Have deep vein thrombosis and pulmonary embolism been reported in patients taking Jakavi (ruxolitinib phosphate)?

Yes, deep vein thrombosis and pulmonary embolism have been reported in patients receiving Jakavi (ruxolitinib phosphate), although thromboembolic event rates in clinical studies of patients with MF and PV were similar between Jakavi and control-treated patients.